Please note: AABB reserves the right to make updates to this program.
Thursday, April 23, 2020
2:00 – 3:00 PM (ET) 7:00 – 8:00 PM (GMT)
Master Program Number: 20EL-526 (see program format numbers below under Registration)
Educational Track: Technical/Clinical
Topic: Cellular Therapies
Intended Audience: Hospitals, Hospital Blood Banks, Medical Directors, Nurses, Physicians, Research Scientists, Residents/Fellows, Scientists, Students (MD, MT, SBB), Technologists
Teaching Level: Intermediate
Director/Moderator: Thomas Spitzer, MD, Director, Cellular Therapy and Transplantation Laboratory, Massachusetts General Hospital, Boston, MA
Speaker: Jonathan Hoggatt, PhD, Assistant Professor of Medicine, Harvard Medical School, Massachusetts General Hospital, Boston, MA
After participating in this educational activity, participants should be able to:
- Discuss historical approaches to hematopoietic stem cell mobilization.
- Describe the benefits and limitations of current stem cell mobilization approaches.
- Discuss a novel mobilization strategy involving the CXCR2 agonist GROβ and the CXCR4 agonist AMD3100.
This program will review the available approaches and the benefits and limitations of each to stem cell mobilization for hematopoietic cell transplantation, and discuss a promising novel, rapid strategy for stem cell mobilization utilizing the CXCR2 agonist GROβ and the CXCR4 agonist AMD3100.
| || ||
|Single Viewer: Live||
|Single Viewer: On-Demand||
|Group Viewing: Live||
|Group Viewing: On-Demand||
|Group Viewing: Live & On-Demand||
Continuing Education Credit
AABB estimates both the live and on-demand version of this eCast each to be eligible for 1 continuing education credits/contact hours for Physicians, California Nurse, California Lab Personnel, Florida Lab Personnel and General Participation credit. The final number of credit(s) and credit types awarded for this program (live or on-demand) will be determined by the program duration. For more information on each credit type please visit our
Continuing Education Credits webpage.
Disclosures for the planners of this event can be found here. Disclosures for the program faculty are provided at the beginning of the program.
Dr. Jonathan Hoggatt is Assistant Professor of Medicine at Harvard Medical School and holds appointments in both the Center for Cancer Research and Center for Transplantation Sciences of Massachusetts General Hospital. Dr. Hoggatt is also a principal faculty member of the Harvard Stem Cell Institute and an affiliate faculty member of the Stem Cell and Regenerative Biology Department at Harvard University. Dr Hoggatt trained with Dr. Louis Pelus at Indiana University School of Medicine and did his post-doctoral training with Dr. David Scadden at Harvard University. Jon is an expert in stem cells and hematopoiesis and his research endeavors focus on translational science in hematopoietic stem cell transplantation. These studies have led to several clinical trials, licensed patents, and high-profile papers in Nature, Nature Medicine, Cell, Blood, Leukemia and others. He holds several patents in novel stem cell therapies and is a co-founder of Magenta Therapeutics.